NEOLEUKIN THERAPEUTICS INC (NLTX)
US64049K2033 - Common Stock
| MRQ (2023-9-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 25.20M | 37.90M | 142.50M | 192.60M | 143.10M | |||
| Marketable Securities | 53.30M | 58.50M | N/A | N/A | N/A | |||
| Receivables | N/A | N/A | N/A | 900.00K | 500.00K | |||
| Other Current Assets | 1.40M | 2.80M | 1.50M | 1.10M | N/A | |||
| Total Current Assets | 79.90M | 99.10M | 144.00M | 194.50M | 143.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 9.20M | 15.90M | 17.20M | 13.70M | 2.80M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Intangibles | N/A | 0.00 | 100.00K | 300.00K | 600.00K | |||
| Other Non-Current Assets | 500.00K | 900.00K | 1.90M | 1.90M | 0.00 | |||
| Total Non-Current Assets | 9.70M | 16.80M | 19.30M | 16.00M | 3.40M | |||
| TOTAL ASSETS | 89.60M | 115.90M | 163.30M | 210.50M | 147.00M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 0.00 | 100.00K | 100.00K | 0.00 | 100.00K | |||
| Accrued Expenses | 1.60M | 10.40M | 8.10M | 6.50M | 3.10M | |||
| Accounts Payable | 3.70M | 500.00K | 500.00K | 1.30M | 1.60M | |||
| Total Current Liabilities | 5.20M | 11.10M | 8.60M | 7.90M | 4.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 200.00K | 100.00K | 100.00K | 100.00K | |||
| Other Non-Current Liabilities | 9.10M | 10.30M | 11.70M | 11.30M | 400.00K | |||
| Total Non-Current Liabilities | 9.20M | 10.50M | 11.80M | 11.40M | 600.00K | |||
| TOTAL LIABILITIES | 14.40M | 21.60M | 20.40M | 19.30M | 5.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -471.90M | -451.10M | -393.50M | -332.80M | -299.50M | |||
| Additional Paid In Capital | 547.10M | 545.40M | 536.40M | 524.00M | 441.20M | |||
| Common Shares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Shares Outstanding | 8.80M | 1.70M | 1.70M | 1.70M | 1.50M | |||
| Tangible Book Value per Share | 8.55 | 55.47 | 84.00 | 112.29 | 94.07 | |||
| Total Shareholders' Equity | 75.20M | 94.30M | 142.90M | 191.20M | 141.70M | |||
| TOTAL LIABILITIES AND EQUITY | 89.60M | 115.90M | 163.30M | 210.50M | 147.00M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Ratio | 15.37 | 8.93 | 16.74 | 24.62 | 30.55 | |||
| Return On Assets (ROA) | -38.25% | -49.66% | -37.16% | -15.81% | -47.24% | |||
| Return On Equity (ROE) | -45.57% | -61.04% | -42.47% | -17.41% | -49.00% | |||
All data in USD